The company will use the funding to advance clinical trials for Tune-401, the epigenetic silencing drug for treating chronic ...

The Durham ID building in downtown Durham, NC holds the North Carolina office of Tune Therapeutics, a growing biotech startup moving into trials. Brian Gordon Launched from a Duke University lab ...

It’s a kind of control that no one has ever tried before in patients,” Tune’s chief scientific officer said Monday.

(Tune Photos) Tune Therapeutics, a biotech company with headquarters in Seattle and Durham, N.C., raised $175 million in one of the largest funding rounds for a Seattle-area startup in recent years.

Launched from a Duke University lab four years ago, the biotech startup Tune Therapeutics announced ... offices in Seattle and at the downtown Durham ID building. Series A and B are the two ...

The funding comes after the biotech company announced in November it was moving into the clinic with its lead drug, which is aimed at treating hepatitis B. Tune Therapeutics, which has dual ...

DURHAM, N.C. & SEATTLE, January 13, 2025--(BUSINESS WIRE)--Leading epigenome editing company Tune Therapeutics (Tune) today announced the completion of over $175M in financing led by New Enterprise ...

Launched from a Duke University lab four years ago, the biotech startup Tune Therapeutics announced ... offices in Seattle and at the downtown Durham ID building. Series A and B are the two ...

Tune Therapeutics, an epigenome-editing company with origins ... The staff is about evenly split between its Durham and Seattle sites, with a few working remotely elsewhere in the country. Investors ...